Shandong Boan Biotechnology (HKG:6955) said its novel CD228-directed antibody-drug conjugate (ADC), BA1302, received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the treatment of squamous non-small cell lung cancer (sqNSCLC) and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.
BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.
The biopharmaceutical company's shares were up 2% in recent trading.